Swansea University experts assess contribution of ultra-rare genetic variation in common epilepsies

Mar 13 2017

Despite progress in understanding the genetics of rare childhood epilepsies, the common adult forms of epilepsy have proven less amenable to traditional gene-discovery analyses.

The Epi4K consortium of experts, which includes academics from Swansea University, decided to assess the contribution of genome-wide ultra-rare genetic variation in the common epilepsies and the results of the study could lay the foundation for future precision medicine.

The study established that there was a clear connection between the genetics of common and rare, severe epilepsies and shows that the variants responsible for epilepsy risk are exceptionally rare in the general population.

The results suggest that the emerging pattern of targeting treatments to the genetic cause in rare devastating epilepsies might also extend to a proportion of common epilepsies. These findings might allow clinicians to broadly explain the cause of these syndromes to patients and lay the foundation for possible precision treatments in the future.

Professor Mark Rees, Dr Owen Pickrell and Dr Seo-Kyung Chung from The Neurology and Neuroscience Research team at Swansea University Medical School are co-authors of the “Ultra-rare genetic variation in common epilepsies: a case-control sequencing study” which has now been published in the February edition of Lancet Neurology.

The Swansea University team’s contribution to the study was the submission over 400 Welsh epilepsy patient samples and anonymised clinical data from the Swansea Neurology Biobank to the Epi4K consortium.

Mark Rees, Professor of Neurology & Molecular Neuroscience Research, Swansea University Medical School said:

This represents one of the largest studies into the genetics of common epilepsy disorders using thousands of patients with epilepsy & healthy controls in conjunction with modern statistical methods. The outcome definitively confirms that common forms of epilepsy have a genetic fingerprint that is not found in a normal control population. It means investigators can proceed with confidence into larger and more specific studies that are meaningful to individual patients and their families.

Dr Pickrell and Dr Chung added:

Our contribution to Epi4K was the result of many years of collecting and archiving epilepsy samples / data across NHS clinics in Wales and patient home visits. Only with patient advocacy, NHS collaboration and a professional Biobanking infrastructure can such large numbers be submitted to meaningful international studies.